ESSA Pharma Inc. (EPIX) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Vancouver, BC, Canada. The current CEO is David Ross Parkinson.
EPIX has IPO date of 2015-03-13, 35 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $9.52M.
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
